Wefight
closedA leading digital health company that creates and develops a Virtual Companion to support every patients with cancer and chronic diseases.
- horizon europe
- oncology
- eit ecosystem
- mental health
- eit health
- tech for patients
- digital care
- patient care
- tech for hospitals and clinics
- tech for medical professionals
- physician support tools
- clinical decision support
- headstart (eit health)
- european health catapult (eit health)
- investor network (eit health)
- cancer care companion
- bridgehead europe (eit health)
- headstart 2017 (eit health)
- investor network 2018 (eit health)
- european health catapult 2018 (eit health)
- product market fit (eit health)
- bridgehead europe 2020 (eit health)
- product market fit 2018 (eit health)
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
€10.0m | Series A | ||
| Total Funding | 000k | ||
| EUR | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 94 % | 129 % | 271 % | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (79 %) | - | - | (81 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (77 %) | - | - | (80 %) | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Dealroom estimates
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.